2018-2023 Analysis of the exploratory biomarkers in muscle biopsy samples and serum samples collected under the 4053-101 (SKIP NMD) trial. Investigator initiated study funded by Sarepta.
2018-2023 EU H202 Solve RD, Solving the unsolved Rare Diseases.
2018-2023. Genetic investigations of unresolved neuromuscular cases. MDA USA.
2019-2024. MRC International Centre for Genomic Research in Neuromuscular Diseases. Medical Research Council. Hanna PI, Muntoni Co-PI
2020-2024: EUH2020. BIND (Brain Involvement iN Dystrophinopathies) consortium grant agreement. Muntoni Coordinator.
2020-2023. D-Brain. Preclinical and clinical studies regarding dystrophin in the brain. Investigator initiated study funded by Sarepta
2020-2023. SMA Registries (SMA REACH-UK). Investigator initiated study funded by Biogen Global and Roche. Muntoni PI.
2020-2023. SMA Registry Light (Biogen UK): Muntoni PI.
2021-2023. SMA BEYOND (SMA beyond motorneuron degeneration: multi-system aspects). EU H2020). Muntoni UK PI.
2022-2024. MDUK. UK Paediatric North Star Network. Muntoni PI, Manzur, Baranello co-PI
2022-2025 UKRI, TRNASNNat. Transforming Delivery, safety and efficacy of nucleic acid therapeutics, from intracellular trafficking to targeting brain, skeletal muscle and heart. Matthew Wood (Oxford, CI, Muntoni and Tabrizi UCL PIs)
2023-2024 MDUK. Variability in the efficacy of antisense oligonucleotides treatment among DMD patients: correlation between genome and transcriptome. Muntoni PI.
2022-24. MDUK. Impact and modulation of modifier genes in LAMA2 muscular dystrophy. Morgan PI, Previtali, Muntoni Co-PI.
2022-2024. Sarepta Therapeutics. Investigator initiated study on鈥� Telehealth and PMO Compassionate Use Longitudinal Study in DMD鈥�. Muntoni PI, Baranello co-PI.
Close
